CERo Therapeutics Holdings - Warrants (13/02/2029) Return on Equity

CERo Therapeutics Holdings - Warrants (13/02/2029) (CEROW) currently reports a ROE of 416.3%. That is above the sector sector average of 11.73%. Use the charts on this page to explore CERo Therapeutics Holdings - Warrants (13/02/2029)'s ROE history and peer comparisons.

CERo Therapeutics Holdings - Warrants (13/02/2029)'s ROE of 416.3% is higher than the its sector sector average of 11.73%. That is roughly 3447.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but CERo Therapeutics Holdings - Warrants (13/02/2029)'s current 416.3% should be judged against industry norms (sector average: 11.73%) and against CEROW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 416.3%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.73%. From there, open related valuation or income-statement pages for CERo Therapeutics Holdings - Warrants (13/02/2029), and consider following CEROW for alerts when major investors trade the stock.